Compare TG Therapeutics Inc (TGTX) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while T Rowe Price Group Inc trades at $115.59 (market cap $25.14B). The key difference: T Rowe Price Group Inc is far larger — about 3× TG Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.43% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TROW | |
|---|---|---|
Market Cap | $8.26B | $25.14B |
Sector | Health | Financials |
52-Week High | $59.06 | $120.16 |
52-Week Low | $26.39 | $86.19 |
Enterprise Value | $8.50B | $21.85B |
Dividend Yield | — | 4.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
